US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer's Disease: Implications for Global Drug Development
Drug development guidelines from regulatory authorities provide important information to sponsors on requirements for clinical evidence needed to support approval of new drugs. In the field of Alzheimer's disease (AD), recently published guidelines are available from EU, US, and Japanese regula...
Saved in:
Main Authors: | Anne Vinther Morant (Author), Henrik Tang Vestergaard (Author), Anders Blædel Lassen (Author), Vaidrius Navikas (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2020-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non‐orphan, Non‐oncology Drugs in the European Union and United States from 2012−2016
by: Anne Vinther Morant, et al.
Published: (2019) -
A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU
by: Fabiany da Costa Gonçalves, et al.
Published: (2022) -
FDA regulatory considerations for oncology drug development
by: Hanlim Moon, et al.
Published: (2024) -
Drug Development for Pediatric Populations: Regulatory Aspects
by: Jochen Zisowsky, et al.
Published: (2010) -
EU adopts legislation to promote drug development for rare diseases
by: Barry Whyte
Published: (2000)